News Release

November 06, 2019

ReAlta Life Sciences, Inc. To Participate In 3rd Annual Complement-Based Drug Development Summit 2019 In Boston, Massachusetts

Norfolk, VA, November 6, 2019 — ReAlta Life Sciences, Inc. announced today that it will participate in the upcoming Complement-based Drug Development Summit being held November 13-15, 2019 in Boston, Massachusetts.

Ulrich Thienel MD, PhD, Chief Executive Officer of ReAlta Life Sciences, Inc. said: “As we prepare to enter the clinic with our first compound, we are excited to join the complement community to share our unique perspectives and experience and build on the considerable progress already achieved by the community.”

ABOUT COMPLEMENT-BASED DRUG DEVELOPMENT SUMMIT  The 3rd Complement-based Drug Development Summit encapsulates the excitement in the field and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges. Attend this event to discover the importance of gathering real world evidence for development and launch of new complement therapeutics, modulate the alternative pathway with a diverse pipeline of targets and modalities, hear clinical trial experience to accelerate your complement therapeutics through the clinic, discover how to create translatable complement assays, and improve translational biomarkers. Attending this meeting will provide you clear clinical understanding of the potential role of complement in common indications and aid in identifying which indication will be the next big opportunity for complement-based therapeutics. This event is expected to draw over 21 companies with representation in the Drug Development, Healthcare, Service Provider, and Research Institute arenas.

ABOUT REALTA — ReAlta Life Sciences, Inc. is an early stage biotech company incorporated in late 2018, and located in Norfolk, Virginia. ReAlta is dedicated to addressing life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms. To support this mission, ReAlta has developed a New Class of Drugs that can address unmet medical needs through unique Multi-Modal Therapeutic Capabilities.

Companies interested in meeting with ReAlta at the 3rd Complement-based Drug Development Summit are asked to contact Tom Filipczak at


Feb 16, 2021

ReAlta Life Sciences Doses First Subject In Phase 1 Healthy Volunteers Study...

Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...

Read More
Dec 03, 2020

ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 For The...

Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...

Read More
Nov 19, 2020

ReAlta Life Sciences Featured In Norfolk Innovation Corridor, Launch Of New Technology...

Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is...

Read More